Henghui Zhang

List of Publications by Year
in descending order

82 papers	1,344 citations	448610 19 h-index	488211 31 g-index
88 all docs	88 docs citations	88 times ranked	2496 citing authors

#	Article	IF	Citations
1	PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients. Cancer Immunology, Immunotherapy, 2022, 71, 111-120.	2.0	11
2	Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. Cancer Biology and Medicine, 2022, 19, 1139-1149.	1.4	4
3	Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. Npj Precision Oncology, 2022, 6, 2.	2.3	17
4	Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer. Current Oncology, 2022, 29, 283-293.	0.9	1
5	Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma. Frontiers in Immunology, 2022, 13, 794217.	2.2	4
6	Soluble Immune-Related Proteins as New Candidate Serum Biomarkers for the Diagnosis and Progression of Lymphangioleiomyomatosis. Frontiers in Immunology, 2022, 13, 844914.	2.2	1
7	Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients. OncoTargets and Therapy, 2022, Volume 15, 353-359.	1.0	4
8	The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma. Hpb, 2021, 23, 1061-1071.	0.1	12
9	Partial recovery of disturbed V-J pairing profiles of T-cell receptor in people living with HIV receiving long-term antiretroviral therapy. Science China Life Sciences, 2021, 64, 152-161.	2.3	1
10	Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma. Translational Oncology, 2021, 14, 100942.	1.7	3
11	Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma. Oncologist, 2021, 26, 173-177.	1.9	23
12	A Machine Learning Approach Yields a Multiparameter Prognostic Marker in Liver Cancer. Cancer Immunology Research, 2021, 9, 337-347.	1.6	10
13	Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma. , 2021, 9, e001967.		6
14	Identification of immune checkpoint and cytokine signatures associated with the response to immune checkpoint blockade in gastrointestinal cancers. Cancer Immunology, Immunotherapy, 2021, 70, 2669-2679.	2.0	4
15	A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer. Npj Precision Oncology, 2021, 5, 36.	2.3	20
16	Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. , 2021, 9, e001942.		22
17	Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.. Journal of Clinical Oncology, 2021, 39, 9063-9063.	0.8	0
18	Single cell transcriptome revealed tumor associated antigen (TAA) profile in lung adenocarcinoma (LUAD). Biomarker Research, 2021, 9, 41.	2.8	1

#	Article	IF	Citations
19	Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. , 2021, 9, e002356.		35
20	Persistent High Percentage of HLA-DR+CD38high CD8+ T Cells Associated With Immune Disorder and Disease Severity of COVID-19. Frontiers in Immunology, 2021, 12, 735125.	2.2	35
21	Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours. EBioMedicine, 2021, 71, 103542.	2.7	6
22	Comparative molecular profiling of distant metastatic and non-distant metastatic lung adenocarcinoma.. Neoplasma, 2021, 68, 253-261.	0.7	1
23	Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics, 2021, 11, 4585-4598.	4.6	39
24	EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma. Aging, 2021, 13, 598-618.	1.4	10
25	The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses. Aging, 2021, 13, 2365-2378.	1.4	15
26	Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. Genome Medicine, 2021, 13, 175.	3.6	12
27	Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report. Frontiers in Oncology, 2021, 11, 767957.	1.3	3
28	Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient WithÂStrong Expression of Programmed Death LigandÂ1. Journal of Thoracic Oncology, 2020, 15, e4-e8.	0.5	3
29	Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy. Biomedicine and Pharmacotherapy, 2020, 129, 110457.	2.5	19
30	An Immunogram for an Individualized Assessment of the Antitumor Immune Response in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 1189.	1.3	6
31	The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-Î± therapy outcomes in chronic hepatitis B patients. BMC Infectious Diseases, 2020, 20, 590.	1.3	4
32	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. Experimental Hematology and Oncology, 2020, 9, 17.	2.0	21
33	Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer. , 2020, 8, e000374.		43
34	Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. , 2020, 8, e000631.		22
35	The mutation profiles of cell-free DNA in patients with oesophageal squamous cell carcinoma who were responsive and non-responsive to neoadjuvant chemotherapy. Journal of Thoracic Disease, 2020, 12, 4274-4283.	0.6	7
36	Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduction and Targeted Therapy, 2020, 5, 192.	7.1	38

#	Article	IF	Citations
37	Prognostic impact of gene copy number instability and tumor mutation burden in patients with resectable gastric cancer. Cancer Communications, 2020, 40, 63-66.	3.7	10
38	Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency. , 2020, 8, e000463.		8
39	Molecular Alterations in Circulating Cell-Free DNA in Patients with Colorectal Adenoma or Carcinoma . Cancer Management and Research, 2020, Volume 12, 5159-5167.	0.9	2
40	VEGF-D: a novel biomarker for detection of COVID-19 progression. Critical Care, 2020, 24, 373.	2.5	77
41	Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report. Thoracic Cancer, 2020, 11, 1094-1098.	0.8	10
42	NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer. Frontiers in Oncology, 2020, 10, 574937.	1.3	29
43	DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Frontiers in Oncology, 2020, 10, 549777.	1.3	26
44	Characterization of the immune microenvironment in brain metastases from different solid tumors. Cancer Medicine, 2020, 9, 2299-2308.	1.3	9
45	Ki-67 versus MammaPrint/BluePrint for assessing luminal type breast cancer.. Journal of Clinical Oncology, 2020, 38, e13673-e13673.	0.8	2
46	Association of HLA class I genotype with outcomes of gastrointestinal cancer patients with immunotherapy.. Journal of Clinical Oncology, 2020, 38, e16551-e16551.	0.8	1
47	Mutation of DNA damage repair genes confers an immune-privileged tumor microenvironment in colorectal cancer with a prognostic value.. Journal of Clinical Oncology, 2020, 38, 4080-4080.	0.8	0
48	Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer.. Journal of Clinical Oncology, 2020, 38, e16014-e16014.	0.8	0
49	Application of MammaPrint test on Chinese patient with breast cancer.. Journal of Clinical Oncology, 2020, 38, e13671-e13671.	0.8	0
50	The association of CD8⁺ T-cell infiltration and PD-L1 expression with prognosis of Chinese pulmonary large cell neuroendocrine carcinoma.. Journal of Clinical Oncology, 2020, 38, e21003-e21003.	0.8	0
51	PD-1 or PD-L1 co-localizes with immune cells for prediction of prognosis in non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, e21029-e21029.	0.8	0
52	The mutation of homologous recombination repair genetics is a potential biomarker for immunotherapy in microsatellite stable colon cancer.. Journal of Clinical Oncology, 2020, 38, 4076-4076.	0.8	6
53	Distinct transcriptional profiles in plasma exosomes associated with recurrence of nasopharyngeal carcinoma patients with standard treatment.. Journal of Clinical Oncology, 2020, 38, 6534-6534.	0.8	0
54	FOXP3 expression in FOXP3+ tumor cells promotes hepatocellular cells metastasis. Translational Cancer Research, 2020, 9, 5868-5881.	0.4	4

#	Article	IF	Citations
55	Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. JAMA Network Open, 2019, 2, e197621.	2.8	25
56	Molecular analysis of cellâ€free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer. Cancer Communications, 2019, 39, 1-5.	3.7	10
57	PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 193.	3.5	61
58	The mutational landscape of MSI-H and MSS colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15122-e15122.	0.8	4
59	Association of high copy number instability (CNI) score with prognosis in patients with gastric cancer after surgical resection.. Journal of Clinical Oncology, 2019, 37, e15552-e15552.	0.8	0
60	The mutational profile analysis of different response to neoadjuvant chemoradiation therapy in local advanced esophageal squamous cell cancer patients.. Journal of Clinical Oncology, 2019, 37, e15560-e15560.	0.8	0
61	The cross talk between the molecular alterations and tumor immunity in the microenvironment in non-small-cell lung carcinoma.. Journal of Clinical Oncology, 2019, 37, e20043-e20043.	0.8	0
62	The mutational profile analysis of extramural vascular invasion in rectal cancer.. Journal of Clinical Oncology, 2019, 37, e15128-e15128.	0.8	0
63	Tumor copy number alteration (CNA) burden as a prognostic factor for overall survival in Chinese gastric cancers.. Journal of Clinical Oncology, 2019, 37, e15555-e15555.	0.8	2
64	Prediction of hepatocellular carcinoma patient survival using machine learning classification rules.. Journal of Clinical Oncology, 2019, 37, e15649-e15649.	0.8	0
65	Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma. American Journal of Translational Research (discontinued), 2019, 11, 1428-1445.	0.0	8
66	Clinical Outcome and Molecular Analysis of a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Mutation V834L. Journal of Thoracic Oncology, 2018, 13, e189-e191.	0.5	2
67	Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. International Journal of Infectious Diseases, 2018, 67, 92-97.	1.5	66
68	Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers. Scientific Reports, 2018, 8, 8990.	1.6	31
69	The mutational landscape of circulating cell free DNA in patients with esophageal squamous cell carcinoma response and non-response to neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2018, 36, e16082-e16082.	0.8	1
70	PD-L1 expression and TMB status in newly diagnosed metastatic non-small cell lung cancer and their effect on prognosis after EGFR-TKI or platinum-based chemotherapy.. Journal of Clinical Oncology, 2018, 36, e24294-e24294.	0.8	0
71	Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers.. Journal of Clinical Oncology, 2018, 36, e17543-e17543.	0.8	0
72	The transcription factor RFX5 is a transcriptional activator of the TPP1 gene in hepatocellular carcinoma. Oncology Reports, 2017, 37, 289-296.	1.2	25

#	Article	IF	Citations
73	Abnormal phenotypic features of IgM+B cell subsets in patients with chronic hepatitis C virus infection. Experimental and Therapeutic Medicine, 2017, 14, 1846-1852.	0.8	2
74	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. Theranostics, 2017, 7, 4753-4762.	4.6	25
75	Identifying tumor promoting genomic alterations in tumor-associated fibroblasts via retrovirus-insertional mutagenesis. Oncotarget, 2017, 8, 97231-97245.	0.8	4
76	Gutâ€derived lymphocyte recruitment to liver and induce liver injury in nonâ€alcoholic fatty liver disease mouse model. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 676-684.	1.4	31
77	Sendai Virus Induces Persistent Olfactory Dysfunction in a Murine Model of PVOD via Effects on Apoptosis, Cell Proliferation, and Response to Odorants. PLoS ONE, 2016, 11, e0159033.	1.1	34
78	Deep sequencing of hepatitis B virus basal core promoter and precore mutants in HBeAg-positive chronic hepatitis B patients. Scientific Reports, 2015, 5, 17950.	1.6	21
79	Abnormal CD4â€‰+â€‰T helper (Th) 1 cells and activated memory B cells are associated with type III asymptomatic mixed cryoglobulinemia in HCV infection. Virology Journal, 2015, 12, 100.	1.4	10
80	Dexamethasone affects mouse olfactory mucosa gene expression and attenuates genes related to neurite outgrowth. International Forum of Allergy and Rhinology, 2015, 5, 907-918.	1.5	16
81	Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. Journal of Experimental and Clinical Cancer Research, 2015, 34, 141.	3.5	186
82	S100A4 promotes liver fibrosis via activation of hepatic stellate cells. Journal of Hepatology, 2015, 62, 156-164.	1.8	133